Pertuzumab (Perjeta) was launched in Germany in March 2013 for use as adjunctive therapy by certain patients with advanced HER2-positive breast cancer. 
The Institute for Quality and Efficiency in Health Care (IQWiG) has conducted an early benefit assessment to determine whether pertuzumab offers an additional benefit when compared with standard therapy.  IQWIG has found that patients with visceral metastases therefore have a survival advantage. However, statements about the possible damage in the form of side effects are not possible. IQWiG sees no evidence here, but an indication of a considerable added value. For patients without visceral metastases and breast cancer with local relapse, there is no additional benefit.

For more details, go to 
https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/pertuzumab_anhaltspunkt... [German]